Lessons learned from the development of imatinib

Leuk Res. 2004 May;28 Suppl 1:S29-38. doi: 10.1016/j.leukres.2003.10.002.
No abstract available

Publication types

  • Review

MeSH terms

  • Benzamides
  • Drug Design*
  • Drug Evaluation, Preclinical / methods
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Fusion Proteins, bcr-abl / metabolism
  • Humans
  • Imatinib Mesylate
  • Neoplasms / drug therapy
  • Piperazines / chemistry
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / chemistry
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use
  • Structure-Activity Relationship

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl